The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis.

We have investigated the importance of interleukin-6 (IL-6) in promoting tumor growth and metastasis. In human primary breast cancers, increased levels of IL-6 were found at the tumor leading edge and positively correlated with advanced stage, suggesting a mechanistic link between tumor cell production of IL-6 and invasion. In support of this hypothesis, we showed that the IL-6/Janus kinase (JAK)/signal transducer and activator of transcription 3 (Stat3) pathway drives tumor progression through the stroma and metastatic niche. Overexpression of IL-6 in tumor cell lines promoted myeloid cell recruitment, angiogenesis, and induced metastases. We demonstrated the therapeutic potential of interrupting this pathway with IL-6 receptor blockade or by inhibiting its downstream effectors JAK1/2 or Stat3. These clinically relevant interventions did not inhibit tumor cell proliferation in vitro but had profound effects in vivo on tumor progression, interfering broadly with tumor-supportive stromal functions, including angiogenesis, fibroblast infiltration, and myeloid suppressor cell recruitment in both the tumor and pre-metastatic niche. This study provides the first evidence for IL-6 expression at the leading edge of invasive human breast tumors and demonstrates mechanistically that IL-6/JAK/Stat3 signaling plays a critical and pharmacologically targetable role in orchestrating the composition of the tumor microenvironment that promotes growth, invasion, and metastasis.

[1]  L. Ivashkiv,et al.  Differential interleukin-6/Stat3 signaling as a function of cellular context mediates Ras-induced transformation , 2010, Breast Cancer Research.

[2]  Hua Yu,et al.  Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. , 2008, The Journal of clinical investigation.

[3]  G. Dranoff,et al.  Combining immunotherapy and targeted therapies in cancer treatment , 2012, Nature Reviews Cancer.

[4]  D. Gabrilovich,et al.  Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species , 2003, Journal of leukocyte biology.

[5]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[6]  D. Levy,et al.  STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. , 2011, Cancer research.

[7]  R. Figlin,et al.  Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. , 2011, Cancer research.

[8]  Hua Yu,et al.  In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses , 2009, Nature Biotechnology.

[9]  Hua Yu,et al.  Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity , 2005, Nature Medicine.

[10]  D. Levy,et al.  Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression. , 2009, Cancer research.

[11]  A. Richardson,et al.  Reciprocal Effects of STAT5 and STAT3 in Breast Cancer , 2009, Molecular Cancer Research.

[12]  Jason Gotlib,et al.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.

[13]  J. Gregg,et al.  Syngeneic mouse mammary carcinoma cell lines: Two closely related cell lines with divergent metastatic behavior , 2005, Clinical & Experimental Metastasis.

[14]  R. Arlinghaus,et al.  Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. , 2005, Cancer research.

[15]  D. Santini,et al.  IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. , 2007, The Journal of clinical investigation.

[16]  D. Gabrilovich,et al.  Coordinated regulation of myeloid cells by tumours , 2012, Nature Reviews Immunology.

[17]  S. Barsky,et al.  A novel human xenograft model of inflammatory breast cancer. , 1999, Cancer research.

[18]  G. Prendergast,et al.  IDO is a nodal pathogenic driver of lung cancer and metastasis development. , 2012, Cancer discovery.

[19]  W. Gerald,et al.  Stat3 Mediates Expression of Autotaxin in Breast Cancer , 2011, PloS one.

[20]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[21]  Hua Yu,et al.  The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. , 2009, Cancer cell.

[22]  M. Colombo,et al.  The terminology issue for myeloid-derived suppressor cells. , 2007, Cancer research.

[23]  Mithat Gönen,et al.  The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. , 2011, The Journal of clinical investigation.

[24]  R. Figlin,et al.  S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. , 2012, Cancer cell.

[25]  S G Hilsenbeck,et al.  Significance of axillary lymph node metastasis in primary breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. Rafii,et al.  Preparing the "soil": the premetastatic niche. , 2006, Cancer research.

[27]  R. Figlin,et al.  Microenvironment and Immunology Targeting Stat3 in the Myeloid Compartment Drastically Improves the in Vivo Antitumor Functions of Adoptively Transferred T Cells , 2022 .

[28]  D. Yoon,et al.  Intracellular Interaction of Interleukin (IL)-32α with Protein Kinase Cϵ (PKCϵ) and STAT3 Protein Augments IL-6 Production in THP-1 Promonocytic Cells* , 2012, Journal of Biological Chemistry.

[29]  Nicholas R. English,et al.  Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.

[30]  Goberdhan P Dimri,et al.  Mammary epithelial cell transformation: insights from cell culture and mouse models , 2005, Breast Cancer Research.

[31]  Z. Werb,et al.  GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. , 2008, Cancer cell.

[32]  Hua Yu,et al.  Tumour immunology: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment , 2007, Nature Reviews Immunology.

[33]  Sun Park,et al.  STAT3 transcriptional factor activated by reactive oxygen species induces IL6 in starvation-induced autophagy of cancer cells , 2010, Autophagy.

[34]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[35]  E. Galun,et al.  Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis , 2012, Clinical and Translational Oncology.

[36]  T. Kishimoto,et al.  Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody , 2004, Springer Seminars in Immunopathology.

[37]  S. Dave,et al.  HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis. , 2011, Cancer research.

[38]  P. Musiani,et al.  Stat3 is required for anchorage‐independent growth and metastasis but not for mammary tumor development downstream of the ErbB‐2 oncogene , 2009, Molecular carcinogenesis.

[39]  T. Putoczki,et al.  Stat3: Linking inflammation to (gastrointestinal) tumourigenesis , 2012, Clinical and experimental pharmacology & physiology.

[40]  W. Gerald,et al.  Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer , 2007, Breast Cancer Research.

[41]  Jeffrey W Pollard,et al.  Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. , 2003, The American journal of pathology.

[42]  W. Gerald,et al.  Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. , 2007, The Journal of clinical investigation.

[43]  P. Sinha,et al.  Reduction of Myeloid-Derived Suppressor Cells and Induction of M1 Macrophages Facilitate the Rejection of Established Metastatic Disease1 , 2005, The Journal of Immunology.

[44]  M. Wicha,et al.  Regulation of Cancer Stem Cells by Cytokine Networks: Attacking Cancer's Inflammatory Roots , 2011, Clinical Cancer Research.

[45]  Karin Jirström,et al.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.

[46]  Hua Yu,et al.  STATs in cancer inflammation and immunity: a leading role for STAT3 , 2009, Nature Reviews Cancer.

[47]  R. Kaplan,et al.  Bone marrow cells in the ‘pre-metastatic niche’: within bone and beyond , 2007, Cancer and Metastasis Reviews.

[48]  K. Hunter,et al.  Mouse Modifier Genes in Mammary Tumorigenesis and Metastasis , 2008, Journal of Mammary Gland Biology and Neoplasia.

[49]  F. Miller,et al.  Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. , 1992, Cancer research.

[50]  F. Vesuna,et al.  Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells , 2009, Oncogene.

[51]  David L Rimm,et al.  Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[52]  J. Pollard,et al.  Microenvironmental regulation of metastasis , 2009, Nature Reviews Cancer.

[53]  Hua Yu,et al.  Stat3-induced S1PR1 expression is critical for persistent Stat3 activation in tumors , 2010, Nature Medicine.